An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant) - Koga, Tomohiro; Takemori, Sachiko; Hagimori, Naoko; Morimoto, Shimpei; Sumiyoshi, Remi; Shimizu, Toshimasa; Hosogaya, Naoki; Fukushima, Chizu; Yamamoto, Hiroshi; Kawakami, Atsushi (Medicine (Baltimore), 2020)
Keywords: Antibodies, Monoclonal, Humanized - therapeutic use; Castleman Disease - drug therapy; Double-Blind Method; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sirolimus - adverse effects; Sirolimus - therapeutic use; Study Protocol Clinical Trial; Treatment Failure; Treatment Outcome